ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0740

Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease

Shivani Garg1, Brad Astor2, S. Sam Lim3, Amish Raval2, Weixiong Zhong2, Sarah Panzer2, Brad Rovin4 and Christie M. Bartels2, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Medicine and Public Health, Madison, WI, 3Emory University, Atlanta, GA, 4Ohio State University, Columbus, OH

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Lupus nephritis, risk assessment, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: Abstracts: Epidemiology & Public Health I

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Patients < 40 years old with lupus nephritis (LN) face 42-fold higher risk of cardiovascular disease (CVD) compared to peers. Traditional CVD risk calculators fail to accurately predict future CVD risk in young LN patients, making decisions to prescribe empiric CVD prevention wrought with uncertainty. While a kidney biopsy is routinely performed to diagnose LN, renal arteriosclerosis (ASCL) is not routinely reported. Renal arteriosclerosis (ASCL) in kidney biopsies at LN diagnosis might represent changes in systemic arteries and could guide CVD risk stratification when most probably don’t take this into account. Thus, in this study we systematically graded renal arteriosclerosis in kidney biopsies at LN diagnosis and examined its role as an early predictor of future incident CVD events.

Methods: Data were abstracted from adult LN patients who underwent diagnostic kidney biopsy between 1994-2021, including socio-demographics, traditional CVD risk factors, and pathology reports. Incident CVD-related deaths and non-fatal CVD events (ischemic heart disease, cerebrovascular accident, transient ischemic attack, and peripheral vascular disease) were adjudicated using published guidelines. Index standard of care kidney biopsies performed to diagnose LN were re-read by a pathologist to grade renal arteriosclerosis (ASCL) by calculating percent luminal narrowing of renal arteries using the Banff criteria. We examined the role of renal ASCL in diagnostic LN biopsies as an early predictor of future CVD using a Cox proportional hazards model in: a) all LN patients; b) those with preserved kidney function defined as chronic kidney disease stages 1-2.

Results: Among 173 adult patients with incident LN, 75% were female and 35% were of Black race or Hispanic ethnicity, and mean age at diagnosis was 38±17 years. Mean eGFR was 79±38 ml/min/1.73m2; 65% of patients had preserved kidney function. We noted 47% and 32% of patients had renal ASCL ≥15% and 25%.

A total of 45 CVD-related deaths and events were observed during up to 18 years of follow-up after LN diagnosis. Mild renal ASCL changes (15% and 25% luminal narrowing) were associated with 2-3-fold higher risk of future CVD (Adjusted HR 2.2 & HR 2.8; Table 1A). The Cox proportional hazard model highlighted accelerated CVD events in patients with renal ASCL ≥15% compared to those without renal ASCL (Fig. 1A). Renal ASCL had higher specificity compared to traditional CV risk factors (Table 2A).

In those with persevered kidney function (n=112), mild renal ASCL predicted 2-fold higher risk of CVD (Adjusted HR 2.2 & HR 2.4; Table 1B). Again, patients with renal ASCL had accelerated CVD events even in this low-risk group (Fig. 1B). Renal ASCL was an early independent risk factor of future CVD with higher specificity than traditional CV risk factors in this low-risk group (Table 2B).

Conclusion: Renal arteriosclerosis found in kidney biopsy at LN diagnosis was a strong, early, and independent risk factor for future CVD events, outperforming traditional CVD risk factors. This observation held consistent even in LN patients with preserved kidney function. This suggests systematic grading of renal ASCL in LN biopsies may help to identify patients who could benefit from aggressive CVD prevention.

Supporting image 1

Figure 1. Survival curves showing CVD event or CVD related death free survival over 18-year follow-up period by 15% or more luminal narrowing of renal arteries (ASCL) in diagnostic LN biopsies in all patients with LN (Panel A.) and in patients with LN with preserved kidney function defined as CKD stages 1_2 (Panel B)

Supporting image 2

Table 1. Multivariable Cox model showing risk factors at lupus nephritis (LN) diagnosis for incident cardiovascular disease (CVD) events or CVD related deaths in: A) All LN patients; B) LN patients with preserved kidney function (CKD stages 1_2)

Supporting image 3

Table 2. Predictive values, sensitivity, and specificity of traditional cardiovascular disease (CVD) risk factors, luminal renal arterial narrowing (renal arteriosclerosis (ASCL)) thresholds, and combined traditional risk factors and renal ASCL thresholds.


Disclosures: S. Garg: None; B. Astor: None; S. Lim: None; A. Raval: None; W. Zhong: None; S. Panzer: None; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; C. Bartels: Pfizer, 5.

To cite this abstract in AMA style:

Garg S, Astor B, Lim S, Raval A, Zhong W, Panzer S, Rovin B, Bartels C. Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/renal-arteriosclerosis-in-index-lupus-nephritis-biopsies-predicts-future-cardiovascular-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/renal-arteriosclerosis-in-index-lupus-nephritis-biopsies-predicts-future-cardiovascular-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology